Profile
Karin Mattsson worked as Director of Research & Development at Biovica International AB from 2017 to 2020.
Prior to that, she worked as a Project Manager at Biovator AB and as Deputy Head of Research & Development at CareDx AB.
She holds a doctorate degree from Karolinska Institutet and a graduate degree from the University of Uppsala.
Former positions of Karin Mattsson
| Companies | Position | End |
|---|---|---|
| BIOVICA INTERNATIONAL AB | Chief Tech/Sci/R&D Officer | 2019-12-31 |
Biovator AB
 Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Corporate Officer/Principal | 2012-03-12 |
CareDx AB
 CareDx AB Medical SpecialtiesHealth Technology CareDx AB develops reagents and kits for low and high resolution human leukocyte antigen typing. Its products include Olerup SSP, Olerup QTYPE, Olerup XM-ONE, Olerup SBT and Olerup Gamma-Type. The comaony was founded by Olle Olerup in 1992 and is headquartered in Saltsjobaden, Sweden. | Corporate Officer/Principal | - |
Training of Karin Mattsson
| University of Uppsala | Graduate Degree |
| Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOVICA INTERNATIONAL AB | Health Technology |
| Private companies | 2 |
|---|---|
Biovator AB
Biovator AB Miscellaneous Commercial ServicesCommercial Services Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009. | Commercial Services |
CareDx AB
CareDx AB Medical SpecialtiesHealth Technology CareDx AB develops reagents and kits for low and high resolution human leukocyte antigen typing. Its products include Olerup SSP, Olerup QTYPE, Olerup XM-ONE, Olerup SBT and Olerup Gamma-Type. The comaony was founded by Olle Olerup in 1992 and is headquartered in Saltsjobaden, Sweden. | Health Technology |
- Stock Market
- Insiders
- Karin Mattsson
